Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s diseaseTopline data from Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025Cash, cash equivalents and marketable securities balance of $192.6M as of September 30, 2025, e ...